Year: 2024

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) — Nexxen International Ltd. (AIM/NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, announces it will participate in a fireside chat and host investor meetings at the RBC Global Technology, Internet, Media and Telecommunications Conference on Tuesday, November 19, 2024, in New York, NY. The fireside chat will be held at 1:20 PM ET on the same date and will be available on live webcast under the “Events and Presentations” section of Nexxen’s investor relations website at https://investors.nexxen.com. For more information, or to schedule a meeting with management, please reach out to your RBC representative. Fireside Chat and Webcast DetailsPresenter: Ofer Druker, Chief Executive Officer Date: Tuesday,...

3D Systems’ PSLA 270 Solution3D Systems’ PSLA 270 solution accelerates time to part for production applications.PSLA 270 solution — new mid-frame projector-based polymer 3D printing platform, Wash 400/Wash 400F and Cure 400 — enables faster production of end-use parts Figure 4® Rigid Composite White & Accura® AMX Rigid Composite White, with early availability in Europe, enables high resolution, high stiffness parts with improved efficiency Range of new print platforms and materials reinforces continued investment in R&D to drive competitive advantageROCK HILL, S.C., Nov. 07, 2024 (GLOBE NEWSWIRE) — Today, 3D Systems (NYSE:DDD) announced several new products it will showcase at Formnext 2024 including advanced printing technologies and materials engineered to help customers meet a variety of application...

NEW YORK and TOKYO, Nov. 07, 2024 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and data consulting services company based in Tokyo, will be virtually presenting and holding one-on-one meetings at the Sidoti Micro-Cap Conference on November 13-14, 2024. HeartCore Chief Executive Officer, Sumitaka Yamamoto, is scheduled to present on Thursday, November 14, 2024 at 11:30 a.m. Eastern time. The presentation will be webcast and available for replay here. To register for the presentation or request one-on-one meetings, please visit www.sidoti.com/events. For additional information or to schedule a one-on-one meeting with HeartCore management, please contact Gateway Group at HTCR@gateway-grp.com. About HeartCore Enterprises, Inc.Headquartered in Tokyo, Japan,...

Also Announces Special Dividend of $0.35 Per Share Fulfilling our Fiscal 2024 Distribution Requirements Total Distributions in the Fiscal Third Quarter Amount to $1.09 Per Share NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company, today announced that its Board of Directors has declared a base quarterly dividend of $0.74 per share for the fiscal third quarter ending November 30, 2024, and an additional special dividend of $0.35 per share fulfilling our fiscal 2024 distribution requirements. Both dividends are payable on December 19, 2024, to all stockholders of record at the close of business on December 4, 2024.  “As a result of the strong overall performance of our portfolio during the fiscal second and third quarters, the board...

ATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) announces the successful completion of the fabrication, installation, commissioning, and startup of its first full-scale commercial Perma-FAS system for PFAS (Per- and Polyfluoroalkyl Substances) destruction at the Company’s Perma-Fix Florida facility. This landmark development in Perma-Fix’s PFAS treatment technology marks a significant step forward in the safe, energy-efficient destruction of PFAS, commonly known as “forever chemicals.” The Perma-FAS system has successfully processed commercial PFAS-containing waste materials, beginning on October 28, with initial rapid turn analytical results showing an effective breakdown of the carbon-fluorine bond characteristics of PFAS at more than 99.99% after 6 hours...

New Purchase Orders for W56: Recent orders for seven W56 electric step vans for immediate delivery upon completion of upfit. Growing Fleet Interest and Demos: Following the FedEx Forward event, Workhorse is experiencing increased parcel delivery fleet interest, with multiple demos planned in California and additional units now in the quoting process. CINCINNATI, Nov. 07, 2024 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today announced it has secured purchase orders from three parcel delivery independent service providers for its W56 step vans. The new orders, received in the 30 days following the Company’s participation at FedEx Forward Service Provider Summit, are for seven W56 electric...

MEXICO CITY, Nov. 07, 2024 (GLOBE NEWSWIRE) — Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the Company”), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central and South America, reports its October 2024 preliminary traffic results. In October, Volaris’ ASM capacity decreased by 6.8% year-over-year due to the Pratt & Whitney engine inspections offset by fewer aircraft groundings following the return of the initial batch of inspected engines. Volaris transported 2.5 million passengers during the month with a load factor of 87.4%, a 2.1 pp decrease from last year. RPMs for the month declined by 9.0%, with Mexican domestic RPMs down 14.4% and international RPMs up 1.5%. When comparing year-over-year RPMs and load factor results it is useful to...

Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen (Grifols), Merus, Soleil, ThirdArc and Incyte, employing Vaccinex’s ActivMAb® technology to generate antibodies to complex antigen targets. In addition, Vaccinex has signed agreements to provide Charles River Labs, OmniAb, Adimab and other undisclosed strategic partners with materials to facilitate their antibody discovery programs using transgenic animal species...

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s Management will participate in the following investor conferences during the month of November: Sidoti Virtual Micro Cap ConferenceFormat: Corporate presentation Date: Thursday, November 14, 2024Time: 2:30 PM ETWebcast Link: click here Stifel 2024 Healthcare ConferenceFormat: Corporate presentation Date: Tuesday, November 19, 2024Time: 3:00 PM ETWebcast Link: click here The webcast of the presentations will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/. About CervoMedCervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders....

Strong financial position with $138 million in cash and investments at close of third quarter BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the third quarter ended September 30, 2024, and provided an update regarding its ongoing activities. Pipeline and Corporate UpdatesDose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety evaluation periodPromising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the bloodThe Company continues to evaluate a range of potential strategic options to maximize shareholder valueFinancial Results for the Quarter Ended...